Derived from A First-In-Class Platform Of Therapeutic Molecular Clusters (TMC), Ag5 Is A Differentiated Molecule That Promises To Be Efficacious In Hard-To-Treat Solid Cancers

Time: 1:30 pm
day: Day One


  •  TMCs are individually unique entities with highly specific physical, chemical and biological properties and represent a new therapeutic modality
  • Ag5 will preferentially kill cancer cells but will spare normal cells due to their REDOX homeostasis, resulting in efficacy in difficult to treat cancers with minimal off-target effects
  • Given that radiotherapy (RT) also kills cells by generation of ROS we hypothesise that in addition to efficacy independent of radiotherapy, Ag5 will also augment RT by amplifying the cell killing effect of intracellular ROS generated by radiation